Ombitasvir/paritaprevir/ritonavir
| Combination of | |
|---|---|
| Ombitasvir | Antiviral (NS5A inhibitor) |
| Paritaprevir | Antiviral (NS3 inhibitor) |
| Ritonavir | PK enhancer (CYP3A4, CYP2D6 inhibitor) |
| Clinical data | |
| Trade names | Technivie, Viekirax, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615036 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| ChEBI | |
| (verify) | |
| Combination of | |
|---|---|
| Dasabuvir | Antiviral |
| Ombitasvir | Antiviral (NS5A inhibitor) |
| Paritaprevir | Antiviral (NS3 inhibitor) |
| Ritonavir | PK enhancer (CYP3A4, CYP2D6 inhibitor) |
| Clinical data | |
| Trade names | Viekira Pak, Viekira XR, Holkira Pak, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614057 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| ChemSpider |
|
| KEGG | |
| ChEBI | |
Ombitasvir/paritaprevir/ritonavir, sold under the brand name Technivie among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ombitasvir, paritaprevir, and ritonavir. Specifically it is used together with dasabuvir or ribavirin for cases caused by hepatitis C virus genotype 1 or 4. Cure rates are around 95%. It is taken by mouth.
It is generally well tolerated. Common side effects include nausea, itchiness, rash, and trouble sleeping. Other side effects include allergic reactions and reactivation of hepatitis B among those previously infected. Use is not recommended in those with significant liver problems. While there is no evidence of harm with use during pregnancy, this use has not been well studied. Each of the medications works by a different mechanism. The ritonavir is present to decrease the breakdown of paritaprevir.
Ombitasvir/paritaprevir/ritonavir with dasabuvir was approved for medical use in the United States in December 2014, without dasabuvir in July 2015, and as extended release in July 2016. It is on the World Health Organization's List of Essential Medicines.